Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real MM: daratumumab-based standard regimens in transplant-ineligible newly diagnosed multiple myeloma
2024-512049-17-00Phase 4Completed
- Sponsor
- University of Turin
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daratumumab, bortezomib, melphalan, prednisone, lenalidomide and 1 more in multiple myeloma (MM) (2 arms), sponsored by University of Turin. Primary endpoint: Progression-free survival. Started Sep 2018; status: completed.
02
Drugs
daratumumabbortezomibmelphalanprednisonelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512049-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512049-17-00.